Lumira Ventures

Managing General Partner Peter van der Velden leads the investment team. Lumira operates a partnership structure where senior partners with scientific, clinical, or operating backgrounds share decision-making authority. The firm has not publicly disclosed a formal investment committee roster, but its organizational model reflects a consensus-driven partnership rather than a single-decision-maker structure.

No. While roughly two-thirds of historical deployment has targeted Canadian-headquartered biotech and medical-device companies, Lumira also invests in US-based life sciences firms, particularly in Boston and San Francisco. The firm co-invests regularly with US crossover and specialist healthcare funds in syndicated rounds that span both geographies.

Lumira invests directly in portfolio companies. The firm does not operate a fund-of-funds program. It structures its own general-partner vehicles, raises limited-partner commitments from institutional investors, and deploys capital directly into private life sciences companies spanning preclinical through late-clinical-stage development.

Lumira regularly co-invests alongside US healthcare specialist funds — confirmed syndicate partners include OrbiMed and venBio — particularly in crossover rounds that precede an IPO or acquisition. The firm's ability to lead rounds in Canadian companies while participating as a syndicate member in US deals reflects a flexible allocation approach that has produced multiple exits to large-cap pharmaceutical acquirers.

Yes. Fusion Pharmaceuticals, a radiopharmaceutical company Lumira backed from its early stages, was acquired by AstraZeneca for approximately $2.4B in 2024 (per the company, March 2024). The broader portfolio has generated multiple public listings including Milestone Pharmaceuticals, and the firm reports its portfolio companies have collectively created over $40B in public-market equity value.

Lumira deploys across the full life-sciences continuum. The firm creates companies at the preclinical stage through its academic-sourcing network, then continues investing through clinical proof-of-concept, Series A and B rounds, and into late-stage crossover financings. Its latest fund, Lumira Ventures IV, closed at $255M in February 2024 with a mandate spanning this stage breadth.